Company: GOOGL
Filing Date: 2025-11-05
Form Type: 424B2
Source: 0001193125-25-267232
Chunk: 1

Company: Alphabet Inc.
Filing Date: 2025-11-05
Form: 424B2
Chunk 1
---
, 2025, which will be the third London business day from the date of pricing of the notes (this settlement cycle is referred to as “T+3”). Under Rule 15c6-1under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), trades in the secondary market are generally required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes on any day prior to the business date before delivery will be required, by virtue of the fact that the notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement and should consult their own advisors. See “Underwriting.” Joint Global Coordinators and Joint Book-Running Managers

| Goldman Sachs & Co. LLC |     | HSBC |     | J.P. Morgan |

Joint Book-Running Managers

| BNP PARIBAS |     | Crédit Agricole CIB |     | Deutsche Bank |

| Barclays |     | Citigroup |     | BofA Securities |     | Mizuho |

| Morgan Stanley |     | RBC Capital Markets |     | Scotiabank |     | Société Générale Corporate & Investment Banking |

| TD Securities |     | US Bancorp |     | Wells Fargo Securities |

Co-Managers

| Academy Securities |     | AmeriVet Securities |     | Bancroft Capital |     | Blaylock Van, LLC |

| CastleOak Securities, L.P. |     | Independence Point Securities |     | Loop Capital Markets |     | MUFG |

| NatWest |     | Penserra Securities LLC |     | R. Seelaus & Co., LLC |     | Ramirez & Co., Inc. |

| Santander |     | Standard Chartered Bank |     | UniCredit |

The date of this prospectus supplement is November 3, 2025.

We are responsible for the information contained and incorporated by reference in this prospectus supplement, the accompanying prospectus and in any related free writing prospectus we prepare or authorize. No person is authorized to give any information or to make any representation that is different from, or in addition to, those contained or incorporated by reference into this prospectus supplement, the accompanying prospectus or any related free writing prospectus that we prepare or authorize. If given or made, such information or representations must not be relied upon as having been authorized by us, and we